Integrating primary and secondary care to optimize hepatitis C treatment: development and evaluation of a multidisciplinary educational Masterclass series.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
01 11 2019
01 11 2019
Historique:
entrez:
30
11
2019
pubmed:
30
11
2019
medline:
23
7
2020
Statut:
ppublish
Résumé
It is increasingly being recognized that the elimination of HCV requires a multidisciplinary approach and effective cooperation between primary and secondary care. As part of a project (HepCare Europe) to integrate primary and secondary care for patients at risk of or infected with HCV, we developed a multidisciplinary educational Masterclass series for healthcare professionals (HCPs) working in primary care in Dublin and Bucharest. This article aims to describe and evaluate the series and examine how this model might be implemented into practice. GPs and other HCPs working in primary care, addiction treatment services and NGOs were invited to eight 1 day symposia (HCV Masterclass series), examining the burden and management of HCV in key populations. Peer-support sessions were also conducted, to give people affected by HCV and community-based organizations working with those directly affected, an update on the latest developments in HCV treatment. One hundred percent of participants 'strongly agreed' or 'agreed' that the Masterclass helped them to appreciate the role of integrated services in 'the management of patients with HCV'. One hundred percent of participants indicated the importance of a 'designated nurse to liaise with hospital services'. An improvement of knowledge regarding HCV management of patients with high-risk behaviour was registered at the end of the course. Integrated approaches to healthcare and improving the knowledge of HCPs and patients of the latest developments in HCV treatment are very important strategies that can enhance the HCV care pathway and treatment outcomes.
Sections du résumé
BACKGROUND
It is increasingly being recognized that the elimination of HCV requires a multidisciplinary approach and effective cooperation between primary and secondary care.
OBJECTIVES
As part of a project (HepCare Europe) to integrate primary and secondary care for patients at risk of or infected with HCV, we developed a multidisciplinary educational Masterclass series for healthcare professionals (HCPs) working in primary care in Dublin and Bucharest. This article aims to describe and evaluate the series and examine how this model might be implemented into practice.
METHODS
GPs and other HCPs working in primary care, addiction treatment services and NGOs were invited to eight 1 day symposia (HCV Masterclass series), examining the burden and management of HCV in key populations. Peer-support sessions were also conducted, to give people affected by HCV and community-based organizations working with those directly affected, an update on the latest developments in HCV treatment.
RESULTS
One hundred percent of participants 'strongly agreed' or 'agreed' that the Masterclass helped them to appreciate the role of integrated services in 'the management of patients with HCV'. One hundred percent of participants indicated the importance of a 'designated nurse to liaise with hospital services'. An improvement of knowledge regarding HCV management of patients with high-risk behaviour was registered at the end of the course.
CONCLUSIONS
Integrated approaches to healthcare and improving the knowledge of HCPs and patients of the latest developments in HCV treatment are very important strategies that can enhance the HCV care pathway and treatment outcomes.
Identifiants
pubmed: 31782501
pii: 5645638
doi: 10.1093/jac/dkz453
pmc: PMC6883391
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
v24-v30Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
Références
N Engl J Med. 2011 Jun 9;364(23):2199-207
pubmed: 21631316
Int J Drug Policy. 2015 Oct;26(10):922-35
pubmed: 26077144
Liver Int. 2013 Aug;33(7):999-1007
pubmed: 23509897
BMC Palliat Care. 2016 Jan 27;15:12
pubmed: 26818836
AIDS Educ Prev. 2014 Apr;26(2):144-57
pubmed: 24694328
Int J Drug Policy. 2015 Oct;26(10):1007-13
pubmed: 26005037
Eur J Gastroenterol Hepatol. 2010 Mar;22(3):270-7
pubmed: 20425880
J Pediatr Oncol Nurs. 2012 Nov-Dec;29(6):316-22
pubmed: 22992428
Clin Infect Dis. 2013 Apr;56(8):1078-84
pubmed: 23362288
Curr Diab Rep. 2016 Aug;16(8):69
pubmed: 27313071
J Subst Abuse Treat. 2016 Aug;67:44-9
pubmed: 27296661
Patient Educ Couns. 2012 Aug;88(2):159-69
pubmed: 22305195
Hum Resour Health. 2013 Oct 01;11:51
pubmed: 24083659
BMC Med Educ. 2005 Dec 19;5:40
pubmed: 16364181
Expert Rev Gastroenterol Hepatol. 2018 Mar;12(3):303-314
pubmed: 29300496
BMJ Open. 2015 Jul 03;5(7):e007920
pubmed: 26141304
Public Health Rep. 2007;122 Suppl 2:83-8
pubmed: 17542460